Brief: Innate Pharma FY Operating Expenses EUR -71.696 Million
27/03/2025 06:00
Mar 27 (Reuters) - Innate Pharma FY basic EPS EUR -0.61. FY EPS continuing operations EUR -0.61 FY operating income EUR -51.575 million FY net income continuing operations EUR -49.471 million FY adjusted operating income EUR -51.575 million
Recent news on Innate Pharma SA
See all newsBrief: Innate Pharma Announces Completion Of Enrollment In Phase 1 Dose Escalation Study Of Iph4502
France's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member